ACR Appropriateness Criteria® nonsurgical treatment for non-small-cell lung cancer: Good performance status/definitive intent Journal Article

  


Authors: Gewanter, R. M.; Rosenzweig, K. E.; Chang, J. Y.; Decker, R.; Dubey, S.; Kong, F. M.; Lally, B. E.; Langer, C. J.; Lee, H. K.; Movsas, B.
Article Title: ACR Appropriateness Criteria® nonsurgical treatment for non-small-cell lung cancer: Good performance status/definitive intent
Abstract: The optimal strategy for the non-surgical definitive treatment of patients with good performance status non-small cell lung cancer (mostly with locally advanced disease) has dramatically evolved over time. This article presents evidence-based data to review this literature. Several decades ago, the standard treatment for most stage III inoperable NSCLC was definitive radiation therapy alone. Randomized trials have since shown superior results with sequential chemotherapy and radiation, and more recently with concurrent chemoradiation, the current standard of care. Studies suggest a limited role for induction or adjuvant systemic therapy in addition to concurrent chemoradiation. The role of altered radiation fractionation techniques, such as hyperfractionation for locally advanced disease or hypofractionation for early stage disease is also discussed. More recently, the application of more advanced radiation techniques has been explored, including intensity modulated radiation therapy (IMRT) and proton beam radiation. Finally, various case variants are presented as examples of state-of-the-art treatment approaches. © 2010 American College of Radiology.
Keywords: cancer survival; cancer surgery; survival rate; clinical trial; intensity modulated radiation therapy; bevacizumab; cisplatin; doxorubicin; erlotinib; advanced cancer; cancer combination chemotherapy; multimodality cancer therapy; clinical trials as topic; paclitaxel; cancer adjuvant therapy; cancer radiotherapy; combined modality therapy; methotrexate; cancer staging; antineoplastic agent; carboplatin; lung toxicity; multiple cycle treatment; etoposide; esophagitis; lung non small cell cancer; antineoplastic combined chemotherapy protocols; carcinoma, non-small-cell lung; lung neoplasms; radiotherapy dosage; cyclophosphamide; continuous infusion; radiation injury; cetuximab; distant metastasis; vinblastine; docetaxel; lung tumor; dysphagia; disease severity; radiation dose fractionation; conservative treatment; gefitinib; practice guidelines as topic; surgical mortality; vindesine; nitrosourea; platinum complex; cancer control; navelbine; mitomycin; radiofrequency ablation; stereotactic body radiation therapy; guideline adherence; amifostine; acute disease; molecularly targeted therapy; proton therapy; esophagus injury
Journal Title: Current Problems in Cancer
Volume: 34
Issue: 3
ISSN: 0147-0272
Publisher: Mosby Elsevier  
Date Published: 2010-05-01
Start Page: 228
End Page: 249
Language: English
DOI: 10.1016/j.currproblcancer.2010.04.001
PUBMED: 20541060
PROVIDER: scopus
DOI/URL:

http://www.scopus.com/inward/record.url?eid=2-s2.0-77953105729&partnerID=40&md5=fd1f7c0df673419f5eae01aead8356d0
Notes: --- - "Cited By (since 1996): 2" - "Export Date: 28 June 2012" - "CODEN: CPRCD" - "Source: Scopus"
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Richard Gewanter
    35 Gewanter
  2. Kenneth E Rosenzweig
    165 Rosenzweig
Related MSK Work